How China is getting serious about developing quality drugs right at home

As Chinese biopharma companies experience substantial growth, China hopes to further foster a domestic drug market.

By Nicole Gray • Dec. 1, 2015

What's driving the rapid rise in dermatology drug prices?

Prices for branded prescription dermatology products increased 500% over six years, according to a recent study.

By Nicole Gray • Nov. 30, 2015

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

In blow to Sanofi/Regeneron, CVS favors Amgen's competing PCSK9 med for its formulary

Once CVS Health determined that Repatha and Praluent were therapeutically equivalent, it became all about price negotiations. 

By Nicole Gray • Nov. 24, 2015

Pharma advertising powerhouse is born with Pfizer, Allergan megamerger

Pfizer alone spent $1.4 billion in measured media last year in the U.S.

By David Kirkpatrick • Nov. 24, 2015

How biopharma companies can thrive in the era of megamergers and shrinking budgets

We spoke with James Crowley at Accenture Life Sciences about what it takes to not only survive, but to shine, in a hyper-competitive market.

By Nicole Gray • Nov. 24, 2015

Annual cost of specialty drugs surpasses median household income

An AARP Policy Institute report aims to highlight the financial impact of soaring drug costs even though the insured don't pay retail prices.

By Heather Caspi • Nov. 23, 2015

Samsung Bioepis close to major EU approval for Enbrel biosimilar

The European Medicines Agency recommended approval of Benepali, heating up the biosimilar market for Enbrel. 

By Nicole Gray • Nov. 23, 2015

Why marketers think they'll win in doctors' new war on DTC drug ads

The American Medical Association's proposed ban on direct-to-consumer prescription drug ads threatens to end a $4.5B ad category and is being slammed by pharma companies, and particularly marketers.

By Natalia Angulo • Nov. 20, 2015

Big pharma trying to quash CA drug price cap effort with massive campaign war chest

J&J, AbbVie, Amgen, Eli Lilly, and BMS all have contributed to a fund aimed at defeating the "California Drug Price Relief Act."

By Nicole Gray • Nov. 20, 2015

IMS 2020 forecast: Drug spending will hit a whopping $1.4 trillion

The spike in spending will be driven by increased uptake in emerging markets and the impact of high-priced specialty drugs, according to the group. 

By Nicole Gray • Nov. 19, 2015

Early scripts for female libido pill Addyi fall flat, Valeant left holding the bag

Only 227 Addyi (flibanserin 100 mg) prescriptions were dispensed in the first few weeks post-launch, and the hits just keep coming for Valeant.

By Nicole Gray • Nov. 19, 2015

In unexpected setback, UK cost regulators reject Amgen's PCSK9 drug

The National Institute for Health and Care Excellence (NICE) decided against including Repatha (evolocumab) on the UK's list of reimbursable drugs due to concerns about cost-effectiveness and clinical outcomes. 

By Nicole Gray • Nov. 19, 2015

Paris attack forces Isis Pharma to again consider name change

The problem is self-evident, but the company is hesitant to give up a brand name that took 25 years to build. 

By Nicole Gray • Nov. 18, 2015

AMA backs ban on direct-to-consumer pharma ads

The group says ads drive patients to seek more expensive treatments even when lower-cost options are available.

By Nicole Gray • Nov. 18, 2015

NEJM joins the fray in drug pricing debate as 2 thought leaders share divergent perspectives

Dr. William W. Chin and Dr. Peter Bach are experienced thought leaders with important positions in the biopharma and medical communities—and they have very different opinions about drug pricing and healthcare sustainability. 

By Nicole Gray • Nov. 16, 2015

Horizon swipes back at Express Scripts as PBM cuts off drugmaker's specialty pharma

According to Express Scripts, Linden Care Pharmacy mainly dispensed Horizon drugs and did not fulfill the network agreement. The PBM has also filed suit against Horizon.

By Nicole Gray • Nov. 12, 2015

AHF: Gilead's new HIV med an attempt to evergreen, avoid patent expiration

Does tenofovir's new, improved side-effect profile make Genvoya a new drug, or just a tweaked version of Stribild?

By Nicole Gray • Nov. 11, 2015

No 'purple pill' for Dr. Reddy's—court sides with AZ, blocks Nexium generic over coloration

A Delaware district court ruled in favor of the British pharma giant and its trademark infringement claims.

By Sy Mukherjee • Nov. 10, 2015

Allergan asks SCOTUS to take a hard look at pharma's controversial 'hard switch' tactic

The company lost in federal court when attempting to pull its Alzheimer's med Namenda in order to force patients over to a new formulation. If the Supremes take the case, it would have industry-wide implications for antitrust laws. 

By Nicole Gray • Nov. 10, 2015

Payers: Forget specialty drug costs—generic prices are crushing our budgets, too

According to insurers, prices for some commonly used generics have increased between 15 to 75 times their original prices.

By Nicole Gray • Nov. 9, 2015

Insys Therapeutics under investigation for pushing powerful pain drug

The main ingredient in Insys's pain drug---fetanyl---is 100 times more powerful than morphine. 

By Nicole Gray • Nov. 6, 2015

A huge untapped opportunity for pharma marketing: Social media engagement with doctors

A recent report from the Deloitte Center for Health Solutions highlights third-party health content providers' successful strategy for engaging physicians in an increasingly digital world, along with ideas for how pharma can increase its social media presence with docs. 

By Nicole Gray • Nov. 6, 2015

Harvard study: Americans' prescription med use may be ballooning along with their waistlines

Is there a correlation between increased prescription drug use and rising obesity levels?

By Nicole Gray • Nov. 5, 2015

The Jardiance effect: Novo hopes Victoza will show heart benefit, but wary of CV study design

The diabetes game has truly changed after the success of Lilly & Boehringer's medication in a major CV outcomes trial.

By Nicole Gray • Nov. 5, 2015

As generic drug savings reach all-time high, experts ponder biosims' long-term impact

U.S. generic drug savings reached a peak of $254 billion in 2014, but biosimilars were not part of the analysis. How will those figures look once biosims enter the equation?

By Nicole Gray • Nov. 5, 2015